145 related articles for article (PubMed ID: 31333122)
1. Expression Profile of VEGF-C, VEGF-D, and VEGFR-3 in Different Grades of Endometrial Cancer.
Oplawski M; Dziobek K; Zmarzły N; Grabarek B; Halski T; Januszyk P; Kuś-Kierach A; Adwent I; Dąbruś D; Kiełbasiński K; Boroń D
Curr Pharm Biotechnol; 2019; 20(12):1004-1010. PubMed ID: 31333122
[TBL] [Abstract][Full Text] [Related]
2. Changes in the Expression Profile of VEGF-A, VEGF-B, VEGFR-1, VEGFR-2 in Different Grades of Endometrial Cancer.
Dziobek K; Opławski M; Grabarek BO; Zmarzły N; Tomala B; Halski T; Leśniak E; Januszyk K; Brus R; Kiełbasiński R; Boroń D
Curr Pharm Biotechnol; 2019; 20(11):955-963. PubMed ID: 31322068
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-8: A potent promoter of human lymphatic endothelial cell growth in gastric cancer.
Shi J; Li YJ; Yan B; Wei PK
Oncol Rep; 2015 Jun; 33(6):2703-10. PubMed ID: 25891418
[TBL] [Abstract][Full Text] [Related]
4. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
Davydova N; Harris NC; Roufail S; Paquet-Fifield S; Ishaq M; Streltsov VA; Williams SP; Karnezis T; Stacker SA; Achen MG
J Biol Chem; 2016 Dec; 291(53):27265-27278. PubMed ID: 27852824
[TBL] [Abstract][Full Text] [Related]
5. Suppression of lymphangiogenesis in human lymphatic endothelial cells by simultaneously blocking VEGF-C and VEGF-D/VEGFR-3 with norcantharidin.
Liu ZY; Qiu HO; Yuan XJ; Ni YY; Sun JJ; Jing W; Fan YZ
Int J Oncol; 2012 Nov; 41(5):1762-72. PubMed ID: 22922710
[TBL] [Abstract][Full Text] [Related]
6. Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer.
Yang H; Kim C; Kim MJ; Schwendener RA; Alitalo K; Heston W; Kim I; Kim WJ; Koh GY
Mol Cancer; 2011 Apr; 10():36. PubMed ID: 21481239
[TBL] [Abstract][Full Text] [Related]
7. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer.
Von Marschall Z; Scholz A; Stacker SA; Achen MG; Jackson DG; Alves F; Schirner M; Haberey M; Thierauch KH; Wiedenmann B; Rosewicz S
Int J Oncol; 2005 Sep; 27(3):669-79. PubMed ID: 16077915
[TBL] [Abstract][Full Text] [Related]
9. Differential mRNA and tissue expression of lymphangiogenic growth factors (VEGF-C and -D) and their receptor (VEGFR-3) during tail regeneration in a gecko.
Blacker HA; Orgeig S
J Comp Physiol B; 2012 Jan; 182(1):109-26. PubMed ID: 21800152
[TBL] [Abstract][Full Text] [Related]
10. Quantitative analysis of lymphangiogenic markers in human gastroenteric tumor.
Yuanming L; Feng G; Lei T; Ying W
Arch Med Res; 2007 Jan; 38(1):106-12. PubMed ID: 17174733
[TBL] [Abstract][Full Text] [Related]
11. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844
[TBL] [Abstract][Full Text] [Related]
12. Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma.
Liu B; Ma J; Wang X; Su F; Li X; Yang S; Ma W; Zhang Y
Anat Rec (Hoboken); 2008 Oct; 291(10):1227-35. PubMed ID: 18561194
[TBL] [Abstract][Full Text] [Related]
13. IGFBP7 functions as a potential lymphangiogenesis inducer in non-small cell lung carcinoma.
Zhao W; Wang J; Zhu B; Duan Y; Chen F; Nian W; Sun J; Zhang B; Tong Z; Chen Z
Oncol Rep; 2016 Mar; 35(3):1483-92. PubMed ID: 26706909
[TBL] [Abstract][Full Text] [Related]
14. Correlation between lymph node metastasis and the expression of VEGF-C, VEGF-D and VEGFR-3 in T1 lung adenocarcinoma.
Maekawa S; Iwasaki A; Shirakusa T; Enatsu S; Kawakami T; Kuroki M; Kuroki M
Anticancer Res; 2007; 27(6A):3735-41. PubMed ID: 17970036
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of VEGF ligands and receptors in prostate cancer.
Woollard DJ; Opeskin K; Coso S; Wu D; Baldwin ME; Williams ED
Prostate; 2013 May; 73(6):563-72. PubMed ID: 23038639
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma.
Jüttner S; Wissmann C; Jöns T; Vieth M; Hertel J; Gretschel S; Schlag PM; Kemmner W; Höcker M
J Clin Oncol; 2006 Jan; 24(2):228-40. PubMed ID: 16344322
[TBL] [Abstract][Full Text] [Related]
17. Lymphangiogenesis in aortic valve stenosis--novel regulatory roles for valvular myofibroblasts and mast cells.
Syväranta S; Helske S; Lappalainen J; Kupari M; Kovanen PT
Atherosclerosis; 2012 Apr; 221(2):366-74. PubMed ID: 22281299
[TBL] [Abstract][Full Text] [Related]
18. VEGF-C, VEGF-D and VEGFR-3 expression in peripheral neuroblastic tumours.
Ramani P; Nash R; Radevsky L; Patel A; Luckett M; Rogers C
Histopathology; 2012 Dec; 61(6):1006-16. PubMed ID: 22804730
[TBL] [Abstract][Full Text] [Related]
19. Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2.
Becker J; Pavlakovic H; Ludewig F; Wilting F; Weich HA; Albuquerque R; Ambati J; Wilting J
Clin Cancer Res; 2010 Mar; 16(5):1431-41. PubMed ID: 20179233
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor (VEGF)-C, VEGF-D, VEGFR-3 and D2-40 expressions in primary breast cancer: Association with lymph node metastasis.
Eroğlu A; Ersöz C; Karasoy D; Sak S
Adv Clin Exp Med; 2017; 26(2):245-249. PubMed ID: 28791841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]